摘要
甲状腺癌是最常见的内分泌恶性肿瘤,其中甲状腺乳头状癌(PTC)的发病率最高,约占甲状腺癌的85%~90%。有关PTC的肿瘤标志物很多,如鼠类肉瘤滤过性毒菌致癌同源体B1(BRAF)、端粒酶逆转录酶、Ki-67、微小RNA146b、PDLIM5等,其中BRAF基因在PTC的发生、发展和预后中发挥重要的作用。文章总结了BRAF基因及其信号通路、BRAF基因在PTC发生发展和预后中的作用、BRAF基因与PTC临床病理特征的相关性、BRAF基因在PTC诊断和治疗中的研究进展等,以供读者参考。
Thyroid cancer is the most common endocrine malignancy,and thyroid carcinoma(PTC)has the highest incidence rale,accounts for about 85%~90%of thyroid carcinoma.There are many markers of PTC,such as murine sarcoma viral oncogene homolog B1(BRAF),telomerase reverse transcriptase,Ki-67,microRNA-146b,PDZ and LIM domain 5(PDLIM5).Among them,BRAF plays an important role in the carcinogenesis,development and prognosis of PTC.This article summarizes the research progress of BRAF signaling pathway,its role in the carcinogenesis,development and prognosis of PTC,its clinical correlation with the clinical pathological characteristics of PTC,and its application in the diagnosis and treatment of PTC to provide the references to readers.
作者
邹婷
潘云
王丽霞
Zou Ting;Pan Yun;Wang Lixia(School of Clinical Medicine,Dali University,Dali 671000,China;Department of Pathology,the First Affiliated Hospital of Dali University,Dali 671000,China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2021年第6期629-634,共6页
Chinese Journal of Oncology
基金
国家自然科学基金(81660037,81960042)
云南省教育厅科学研究基金项目(2020Y0568)
云南省高校分子病理重点实验室[云教科(2016)37号]
大理大学肿瘤分子病理学科技创新团队[理大校发(2019)13号]。
